JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non-Inflammatory Breast Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non-Inflammatory Breast Cancer
Hamdi, K; Blancato, J; Goerlitz, D; Islam, MD; Neili, B; Abidi, A; Gat, A; Ayed, F Ben; Chivi, S; Loffredo, CA; Jillson, I; Elgaaied, A Benammar; Marrakchi, R;
  PDF(new window)
 Abstract
Recent discovery showing the presence of microRNAs (miRNAs) in the circulation sparked interest in their use as potential biomarkers. Our previous studies showed the diagnostic potential of miR-451 as a serological marker for inflammatory breast cancer (IBC), miR-337-5p and miR-30b for non-inflammatory breast cancer (non-IBC). The aim of this study is to investigate the prognostic values of circulating miRNAs by comparing the amounts of 12 circulating miRNAs in the serum of IBC and non-IBC from Tunisian breast cancer patients, and by determinating whether correlated pairs of miRNAs could provide useful information in the diagnosis of IBC and non-IBC patients. TaqMan qPCR was performed to detect circulating expression of miRNAs in serum of 20 IBC, 20 non-IBC and 20 healthy controls. Nonparametric rank Spearman rho correlation coefficient was used to examine the prognostic value of miRNAs and to assess the correlation profile between miRNAs expression. Further, a large number of miRNAs were highly correlated (rho>0.5) in both patients groups and controls. Also, the correlations profiles were different between IBC, non-IBC and healthy controls indicating important changes in molecular pathways in cancer cells. Our results showed that miR-335 was significantly overexpressed in premenopausal non-IBC patients; miR-24 was significantly overexpressed in non-IBC postmenopausal patients. Patients with previous parity had higher serum of miR-342-5p levels than those without. Furthermore, patients with HER2+ IBC present lower serum levels of miR-15a than patients with HER2-disease. Together, these results underline the potential of miRNAs to function as diagnostic and prognostic markers for IBC and non-IBC, with links to the menopausal state, Her2 status and parity.
 Keywords
Breast cancer;inflammatory breast cancer;circulating miRNAs;biomarker. prognostic;diagnostic;
 Language
English
 Cited by
 References
1.
Anfossi S, Giordano A, Gao H, et al (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One, 9, 83113. crossref(new window)

2.
Chen C, Ridzon DA, Broomer AJ, et al (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, e179. crossref(new window)

3.
Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006. crossref(new window)

4.
Cittelly DM, Das PM, Salvo VA, et al (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31, 2049-57. crossref(new window)

5.
Cortez MA, Bueso-Ramos C, Ferdin J, et al (2011). MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol, 8, 467-77. crossref(new window)

6.
Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14. crossref(new window)

7.
Dawood S, Cristofanilli M (2011). Inflammatory breast cancer: what progress have we made? Oncol, 25, 264-73.

8.
Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23. crossref(new window)

9.
Fang Z, Tang J, Bai Y, et al (2015). Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res, 34, 86. crossref(new window)

10.
Gaziel-Sovran A, Segura MF, Di Micco R, et al (2011). miR- 30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 20, 104-18. crossref(new window)

11.
Hagrass HA, Sharaf S, Pasha HF, et al (2015). Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer, 6, 281-7.

12.
Hamdi K, Goerlitz D, Stambouli N, et al (2014). miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer. Springerplus, 3, 636. crossref(new window)

13.
Hatse S, Brouwers B, Dalmasso B, et al (2014). Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One, 9, 110644. crossref(new window)

14.
Hausler SF, Keller A, Chandran PA, et al (2010). Whole bloodderived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer, 103, 693-700. crossref(new window)

15.
Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82. crossref(new window)

16.
Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26. crossref(new window)

17.
Kodahl AR, Lyng MB, Binder H, et al (2014). Novel circulating microRNA signature as a potential non-invasive multimarker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol, 8, 874-83. crossref(new window)

18.
Konishi H, Ichikawa D, Komatsu S, et al (2012). Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 106, 740-7. crossref(new window)

19.
Li X, Abdel-Mageed AB, Mondal D, et al (2013). MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med, 6, 74-80.

20.
Liu YX, Long XD, Xi ZF, et al (2014). MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int, 2014, 482926.

21.
Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. crossref(new window)

22.
Lodes MJ, Caraballo M, Suciu D, et al (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One, 4, 6229. crossref(new window)

23.
Lugli G, Cohen AM, Bennett DA, et al (2015). Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers. PLoS One, 10, 139233.

24.
Luo Q, Li X, Li J, et al (2013). MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol, 43, 1212-8. crossref(new window)

25.
Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8. crossref(new window)

26.
Nassar FJ, El Sabban M, Zgheib NK, et al (2014). miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. PLoS One, 9, 107566. crossref(new window)

27.
Palmero EI, de Campos SG, Campos M, et al (2011). Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol, 34, 363-70. crossref(new window)

28.
Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90. crossref(new window)

29.
Sayed D, Abdellatif M (2011). MicroRNAs in development and disease. Physiol Rev, 91, 827-87. crossref(new window)

30.
Schwarzenbach H, Hoon DS, Pantel K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11, 426-37. crossref(new window)

31.
Schwarzenbach H, Nishida N, Calin GA, et al (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol, 11, 145-56. crossref(new window)

32.
Shapira I, Oswald M, Lovecchio J, et al (2014). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer, 110, 976-83. crossref(new window)

33.
Shinden Y, Akiyoshi S, Ueo H, et al (2015). Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res, 35, 123-7.

34.
Simpson RJ, Lim JW, Moritz RL, et al (2009). Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics, 6, 267-83. crossref(new window)

35.
Tomimaru Y, Eguchi H, Nagano H, et al (2012). Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol, 56, 167-75. crossref(new window)

36.
Van der Auwera I, Limame R, van Dam P, et al (2010). Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer, 103, 532-41. crossref(new window)

37.
Wang F, Zheng Z, Guo J, et al (2010). Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol, 119, 586-93. crossref(new window)

38.
Wu C, Wang C, Guan X, et al (2014). Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One, 9, 92292. crossref(new window)

39.
Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol, 2011, 597145.

40.
Wu Q, Wang C, Lu Z, et al (2012). Analysis of serum genomewide microRNAs for breast cancer detection. Clin Chim Acta, 413, 1058-65. crossref(new window)

41.
Yamauchi H, Woodward WA, Valero V, et al (2012). Inflammatory breast cancer: what we know and what we need to learn. Oncologist, 17, 891-9. crossref(new window)

42.
Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60. crossref(new window)

43.
Zeng X, Xiang J, Wu M, et al (2012). Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One, 7, 46367. crossref(new window)

44.
Zhang G, Liu Z, Cui G, et al (2014). MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol, 35, 11137-45. crossref(new window)

45.
Zhu W, Qin W, Atasoy U, et al (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes, 2, 89. crossref(new window)